Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type TP53 status confers therapeutic sensitivity to Venetoclax in patients with Chronic Lymphocytic Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor